<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3179">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425632</url>
  </required_header>
  <id_info>
    <org_study_id>TAU-284-17</org_study_id>
    <nct_id>NCT01425632</nct_id>
  </id_info>
  <brief_title>A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis</brief_title>
  <official_title>A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are: to confirm the superiority of TAU-284 over placebo after
      two weeks of administration to pediatric patients with perennial allergic rhinitis, and to
      investigate the dose response, safety, and plasma concentrations of TAU-284.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, 3-arm parallel-group comparative
      study to confirm the superiority of TAU-284 over placebo after two weeks of administration
      of TAU-284 (10 mg/day or 20 mg/day) or placebo to pediatric patients with perennial allergic
      rhinitis, with &quot;the change from baseline in total nasal symptom score (total score for the
      three major nasal symptoms [sneezing, rhinorrhea, and nasal congestion])&quot; as the primary
      endpoint; and to investigate the dose response, safety, and plasma concentrations of
      TAU-284.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion] (at Final Evaluation)</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total score for the three major nasal symptoms (sneezing, rhinorrhea, and nasal congestion) were rated on 4-point scale ranging from 0 (no symptoms) to 3 (severe) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Nasal Symptom Scores (Sneezing, Rhinorrhea, Nasal Congestion, and Impairment in Daily Activities)</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Individual Scores for Local Nasal Findings (Rhinoscopic Findings)</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity Score</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Adverse Drug Reactions</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Unchanged TAU-284 (Bepotastine Besilate) (at a Total of 3 Time Points, i.e., Before and 2 (±1) Hours After Study-drug Administration at Week 1 and Before Study-drug Administration at Week 2)</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">490</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>TAU-284 Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU-284 High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAU-284</intervention_name>
    <description>TAU-284 Low</description>
    <arm_group_label>TAU-284 Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAU-284</intervention_name>
    <description>TAU-284 High</description>
    <arm_group_label>TAU-284 High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 7 and 15 years

          -  Patients with a weight of at least 20 kg

          -  Patients who have received a diagnosis of perennial allergic rhinitis according to
             the diagnostic criteria

          -  Patients with a mean rhinorrhea score of at least 2 and a mean total score for the
             three major nasal symptoms [sneezing, rhinorrhea, and nasal congestion] of at least 4
             on the basis of symptoms recorded in the nasal allergy diary during the observation
             period

        Exclusion Criteria:

          -  Patients with vasomotor rhinitis or eosinophilic rhinitis

          -  Patients who have concurrent nasal disease that may affect the efficacy of TAU-284

          -  Patients with a history of any of the nasal surgical procedures

          -  Patients who have a positive result for pollen antigens which are dispersed during
             the study period

          -  Patients who have a positive result for dog dander or cat dander antigen

          -  Patients with current or previous history of drug allergy

          -  Patients who concurrently have renal function abnormalities that may cause safety
             problems
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimihiro Okubo, M.D. Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Otorhinolaryngology, Nippon Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reserch site</name>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reserch site</name>
      <address>
        <city>Hokuriku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reserch site</name>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reserch site</name>
      <address>
        <city>Kinki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reserch site</name>
      <address>
        <city>Kyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>November 10, 2015</lastchanged_date>
  <firstreceived_date>August 28, 2011</firstreceived_date>
  <firstreceived_results_date>September 17, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAU-284</keyword>
  <keyword>Bepotastine besilate</keyword>
  <keyword>Histamine H1 receptor antagonists</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TAU-284 Low</title>
          <description>TAU-284 5mg twice daily for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>TAU-284 High</title>
          <description>TAU-284 10mg twice daily for 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>TAU-284 placebo twice daily for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TAU-284 Low</title>
          <description>TAU-284 5mg twice daily for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>TAU-284 High</title>
          <description>TAU-284 10mg twice daily for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>TAU-284 placebo twice daily for 2 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="161"/>
                <measurement group_id="B2" value="166"/>
                <measurement group_id="B3" value="163"/>
                <measurement group_id="B4" value="490"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11.2" spread="2.5"/>
                <measurement group_id="B2" value="11.4" spread="2.3"/>
                <measurement group_id="B3" value="11.2" spread="2.5"/>
                <measurement group_id="B4" value="11.2" spread="2.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="62"/>
                <measurement group_id="B2" value="64"/>
                <measurement group_id="B3" value="72"/>
                <measurement group_id="B4" value="198"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="99"/>
                <measurement group_id="B2" value="102"/>
                <measurement group_id="B3" value="91"/>
                <measurement group_id="B4" value="292"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion] (at Final Evaluation)</title>
        <description>Total score for the three major nasal symptoms (sneezing, rhinorrhea, and nasal congestion) were rated on 4-point scale ranging from 0 (no symptoms) to 3 (severe) .</description>
        <time_frame>Baseline and Week 2</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAU-284 Low</title>
            <description>TAU-284 5mg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>TAU-284 High</title>
            <description>TAU-284 10mg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>TAU-284 placebo twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="161"/>
                  <measurement group_id="O2" value="166"/>
                  <measurement group_id="O3" value="163"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion] (at Final Evaluation)</title>
            <description>Total score for the three major nasal symptoms (sneezing, rhinorrhea, and nasal congestion) were rated on 4-point scale ranging from 0 (no symptoms) to 3 (severe) .</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.84" spread="0.12"/>
                  <measurement group_id="O2" value="-0.92" spread="0.12"/>
                  <measurement group_id="O3" value="-0.70" spread="0.12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]</title>
        <time_frame>Week 2</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Nasal Symptom Scores (Sneezing, Rhinorrhea, Nasal Congestion, and Impairment in Daily Activities)</title>
        <time_frame>Week 2</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Individual Scores for Local Nasal Findings (Rhinoscopic Findings)</title>
        <time_frame>Week 2</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity Score</title>
        <time_frame>Week 2</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events and Adverse Drug Reactions</title>
        <time_frame>Week 2</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of Unchanged TAU-284 (Bepotastine Besilate) (at a Total of 3 Time Points, i.e., Before and 2 (±1) Hours After Study-drug Administration at Week 1 and Before Study-drug Administration at Week 2)</title>
        <time_frame>Week 2</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TAU-284 Low</title>
          <description>TAU-284 5mg twice daily for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>TAU-284 High</title>
          <description>TAU-284 10mg twice daily for 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>TAU-284 placebo twice daily for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials, Information Desk</name_or_title>
      <organization>Mitsubishi Tanabe Pharma Corporation</organization>
      <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
